<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Bioeng Biotechnol</journal-id><journal-id journal-id-type="iso-abbrev">Front Bioeng Biotechnol</journal-id><journal-id journal-id-type="publisher-id">Front. Bioeng. Biotechnol.</journal-id><journal-title-group><journal-title>Frontiers in Bioengineering and Biotechnology</journal-title></journal-title-group><issn pub-type="epub">2296-4185</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7238949</article-id><article-id pub-id-type="doi">10.3389/fbioe.2020.00328</article-id><article-categories><subj-group subj-group-type="heading"><subject>Bioengineering and Biotechnology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Protein Network Studies on PCOS Biomarkers With S100A8, Druggability Assessment, and RNA Aptamer Designing to Control Its Cyst Migration Effect</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Manibalan</surname><given-names>Subramaniyan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/804061/overview"/></contrib><contrib contrib-type="author"><name><surname>Shobana</surname><given-names>Ayyachamy</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/881334/overview"/></contrib><contrib contrib-type="author"><name><surname>Kiruthika</surname><given-names>Manickam</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Achary</surname><given-names>Anant</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/954866/overview"/></contrib><contrib contrib-type="author"><name><surname>Swathi</surname><given-names>Madasamy</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/938056/overview"/></contrib><contrib contrib-type="author"><name><surname>Venkatalakshmi</surname><given-names>Renganathan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/955278/overview"/></contrib><contrib contrib-type="author"><name><surname>Thirukumaran</surname><given-names>Kandasamy</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/821755/overview"/></contrib><contrib contrib-type="author"><name><surname>Suhasini</surname><given-names>K.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Roopathy</surname><given-names>Sharon</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Centre for Research, Kamaraj College of Engineering and Technology</institution>, <addr-line>Madurai</addr-line>, <country>India</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Biotechnology, Kamaraj College of Engineering and Technology</institution>, <addr-line>Madurai</addr-line>, <country>India</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Quan Zou, University of Electronic Science and Technology of China, China</p></fn><fn fn-type="edited-by"><p>Reviewed by: Ankush Sharma, University of Oslo, Norway; Qing Li, Huntsman Cancer Institute, University of Utah, United States</p></fn><corresp id="c001">*Correspondence: Subramaniyan Manibalan, <email>manibalanbt@gmail.com</email></corresp><fn fn-type="other" id="fn004"><p>This article was submitted to Bioinformatics and Computational Biology, a section of the journal Frontiers in Bioengineering and Biotechnology</p></fn></author-notes><pub-date pub-type="epub"><day>13</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>8</volume><elocation-id>328</elocation-id><history><date date-type="received"><day>04</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>25</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Manibalan, Shobana, Kiruthika, Achary, Swathi, Venkatalakshmi, Thirukumaran, Suhasini and Roopathy.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Manibalan, Shobana, Kiruthika, Achary, Swathi, Venkatalakshmi, Thirukumaran, Suhasini and Roopathy</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>The prevalence of polycystic ovary syndrome (PCOS) has been gradually increasing among adult females worldwide. Laparoscopy drilling on ovary is the only available temporary solution with a high incidence of reoccurrence. S100A8 with S100A9 complex is believed to facilitate the cyst migration in PCOS condition. The high evident protein interaction network studies between PCOS biomarkers, cancer invasion markers, and the interactors of S100A8 confirm that this protein has strong interaction with other selective PCOS biomarkers, which may be associative in the immature cyst invasion process. Through the network studies, intensive structural and pathway analysis, S100A8 is identified as a targetable protein. In this research, the non-SELEX <italic>in silico</italic> method is adapted to construct RNA Library based on the consensus DNA sequence of Glucocorticoid Response Element (GRE) and screened the best nucleotide fragments which are bound within the active sites of the target protein. Selected sequences are joined as a single strand and screened the one which competitively binds with minimal energy. <italic>In vitro</italic> follow-up of this computational research, the designed RNA aptamer was used to infect the MCF7 cell line through Lipofectamine 2000 mediated delivery to study the anti-cell migration effect. Wound Scratch assay confirms that the synthesized 18-mer oligo has significant inhibition activity toward tumor cell migration at the cellular level.</p></abstract><kwd-group><kwd>network analysis</kwd><kwd>druggability</kwd><kwd>RNA aptamer</kwd><kwd>lim method</kwd><kwd>pcos targets</kwd><kwd>protein network</kwd></kwd-group><counts><fig-count count="6"/><table-count count="6"/><equation-count count="0"/><ref-count count="33"/><page-count count="9"/><word-count count="0"/></counts></article-meta></front><body><sec id="S1"><title>Introduction</title><p>Nucleotide aptamers are successfully explored as better therapeutics to treat diseases and disorders. Time-consuming low-throughput procedures have been in practice to design the aptamers <italic>in vitro</italic> (<xref rid="B12" ref-type="bibr">Ghavami et al., 2009</xref>). Therefore, <italic>in silico</italic> non-SELEX approach is the better choice to perform the selection of aptamers, which involves the construction of an oligonucleotide library without amplification and binding them with suitable target protein unlike SELEX (<xref rid="B3" ref-type="bibr">Berezovski et al., 2006</xref>; <xref rid="B29" ref-type="bibr">Tseng et al., 2011</xref>). Designing the RNA aptamer for the validated biomarker helps us to normalize the disease state at the genetic level. Hence, delivering a well-designed aptamer against response elements (REs) can control the strange translation of the target gene. REs are the critical elements involved in the activation of target gene regulation. Inhibiting biomarkers of specific pathophysiological conditions at the molecular level is a better choice to oversee the disease (<xref rid="B26" ref-type="bibr">Strimbu and Tavel, 2010</xref>). Target validation is one of the necessary procedures in drug discovery protocol. Since the exact cause of polycystic ovary syndrome (PCOS) is imprecise (<xref rid="B25" ref-type="bibr">Sir-Petermann et al., 2002</xref>), it is tedious to identify the best target clinically. Assay on endometrial cell migration is one of the diagnostic tools to identify the complications of this syndrome, and metformin has a proven attenuating effect on the invasion of endometrial cells of diseased women (<xref rid="B28" ref-type="bibr">Tan et al., 2011</xref>). Previously, researchers have found that 500 biomarkers are prevalent in PCOS (<xref rid="B9" ref-type="bibr">Dai and Lu, 2012</xref>). In this research work, we focused on S100A8 protein which is one of the important biomarkers in PCOS. Protein&#x02013;protein interaction network (PPIN) is used to identify the associative proteins and its pathways in PCOS. Additionally, druggable properties of S100A8 were studied through pocket analysis. Besides, the aptamer library for specific RE of S100A8 was constructed by a non-SELEX fragment approach. The best aptamer sequence was screened through quality assessments, such as affinity and stability parameters.</p></sec><sec sec-type="materials|methods" id="S2"><title>Materials and Methods</title><sec id="S2.SS1"><title>Network Profile of S100A8 in Polycystic Ovary Syndrome and Enrichment Analysis</title><p>Interactors of S100A8 are obtained from BioGRID<sup>3</sup>.<sup>5</sup>, a dataset repository (<xref rid="B18" ref-type="bibr">Oughtred et al., 2019</xref>), and the molecular interaction network was constructed in STRING Database (<xref rid="B27" ref-type="bibr">Szklarczyk et al., 2019</xref>). Biomarkers specific to PCOS and cancer cell invasion are retrieved from the recent research articles (<xref rid="B8" ref-type="bibr">Daan et al., 2016</xref>; <xref rid="B15" ref-type="bibr">Lu et al., 2017</xref>; <xref rid="B10" ref-type="bibr">Gerashchenko et al., 2019</xref>) and are used to construct another network. Both the networks were merged to find the first shell interactors of S100A8. Cytoscape 3.7.2 is employed to merge the networks and find proteins which are associated with S100A8. Pathways of S100A8 and its clusters are identified by using ClueGO, a Cytoscape application for clustering the functional network by terms or pathways (<xref rid="B5" ref-type="bibr">Bindea et al., 2009</xref>). Molecular functions of Gene Ontology (GO), Reactome Pathway Database (<xref rid="B7" ref-type="bibr">Croft et al., 2011</xref>), and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways are used as resources for enrichment analysis. <italic>P</italic>-value 0.005 is set as a significance to select the clusters of S100A8.</p></sec><sec id="S2.SS2"><title>Structure and Druggability Studies on S100A8</title><p>Druggability analysis is used to predict the receptiveness and stability of drug target. Physiochemical and geometric properties such as number of pockets, druggable score, and pocket volume determine the efficiency of the target candidate. DoGSite Scorer is used for binding site prediction analysis and druggability assessment, which is based on heavy-atom coordinates employing support vector machines (SVMs) (<xref rid="B30" ref-type="bibr">Volkamer et al., 2012</xref>). Pocket volume, lipophilic character, and pocket enclosures were accounted for simple score calculation to suggest the competence of targetability. Three-dimensional structure of the target was retrieved from PDB (ID: 5HLV) and used for the druggable screening.</p></sec><sec id="S2.SS3"><title>Glucocorticoid Response Elements for S100A8</title><p>REs are the inducers of the receptor and ligand interaction which results in the expression or activation of a particular protein. Since the aptamers are crucial elements in the control of target expression so we decide to design RNA oligomer against specific PCOS targets. Glucocorticoid RE (GRE) (<xref rid="B14" ref-type="bibr">Hsu et al., 2005</xref>), hypoxia RE (HRE) (<xref rid="B22" ref-type="bibr">Rees et al., 2001</xref>), antioxidant RE (ARE) (<xref rid="B17" ref-type="bibr">Nioi et al., 2003</xref>), and interferon gamma (INF-&#x003b3;) RE (IRE) (<xref rid="B32" ref-type="bibr">Yang et al., 1990</xref>) are identified as the influencing REs of the S100A8 gene. Specifically, GREs have the proficiency to inhibit S100A8 through the downregulation of leukocyte transmigration. Glucocorticoids also induce the expression of inhibition factor for macrophage migration, which ultimately downregulates the cyst inflammation. The earlier research report shows that GRE consists of two half-sites with three spacer bases; the consensus pseudo palindromic sequence of GRE is 5&#x02032; C<underline>AGAACA</underline><bold>TCA</bold>TGTTCTGA 3&#x02032; (<xref rid="B31" ref-type="bibr">Weikum et al., 2017</xref>).</p></sec><sec id="S2.SS4"><title>Nucleotide Fragment Library Construction</title><p>RNA Composer utilizes the Dot-Bracket format notation of the secondary structure sequence to model the RNA, and the 3D element of modeled RNA was chosen from RNA Frabase (<xref rid="B4" ref-type="bibr">Biesiada et al., 2016</xref>). RE is a sequence, which binds with the receptor and plays a crucial role in expression, so the RNA analog library of specific RE was created to mimic the inhibitory action. The consensus sequence was segregated as fragments in such a way that six nucleotides at a stretch were taken per fragment (<xref ref-type="fig" rid="F4">Figure 4A</xref>) for analog library construction. Resulted library sequences were later utilized for binding studies with the target by RNA-Lim method and recognized the various conformations of fragments bound in the active sites of the protein (<xref rid="B13" ref-type="bibr">Hall et al., 2015</xref>). Fragments which bound on active sites are selected to design the high pr&#x000e9;cised aptamer model. Diversity in the exhibited conformations of ssRNA&#x02013;protein complexes was meticulously sampled to construct a fragment library. MC-Fold | MC-Sym pipeline was employed to obtain the secondary and tertiary structures of the constructed aptamer (<xref rid="B21" ref-type="bibr">Parisien and Major, 2008</xref>). The proposed mechanism for PCOS control through the aptamer binding on S100A8 is illustrated in <xref ref-type="fig" rid="F2">Figure 2</xref>. Refinement on docking results of their chain-forming poses was done in Molecular Operating Environment (MOE) suit (<xref rid="B1" ref-type="bibr">Ahirwar et al., 2016</xref>). The fragment-based approach was adopted for competent docking with S100A8 (<xref rid="B1" ref-type="bibr">Ahirwar et al., 2016</xref>); this unusual method has numerous advantages over conventional rigid based docking.</p></sec><sec id="S2.SS5"><title>Affinity and Stability Studies of the Designed Aptamer</title><p>PatchDock tool is efficiently used to study the binding properties of designed aptamers with target protein (<xref rid="B23" ref-type="bibr">Schneidman-Duhovny et al., 2005</xref>). Based on the global binding energy, FireDock is employed to decipher the docked result by flexible refinements rather than the rigidity of protein and also it optimizes the side-chain residues, which minimizes the rigid body conformation of the interactive protein (<xref rid="B16" ref-type="bibr">Mashiach et al., 2008</xref>). Previously, it was reported that the stability of RNA will be analyzed by the inverted repeats which form stable hairpin loops (<xref rid="B1" ref-type="bibr">Ahirwar et al., 2016</xref>). Oligoanalyzer is an inclusive oligonucleotide scrutinizer employed to check the hairpin loop and stability of the designed aptamer (<xref rid="B19" ref-type="bibr">Owczarzy et al., 2008</xref>).</p></sec><sec id="S2.SS6"><title>Anti-migration by Scratch Wound Healing Assay on Cell Lines</title><p>MCF-7 cells were seeded into a 24-well tissue culture plate containing antibiotic-free minimal essential medium (MEM) and incubated for 24 h at 37&#x000b0;C with 5% CO<sub>2</sub>. Sterile microtip was used to a make scratch on the 80% confluence monolayer (<xref rid="B6" ref-type="bibr">Camorani et al., 2014</xref>). The culture medium was immediately replaced with fresh medium to remove the dislodged cells. Then, 20 nmol/l of the designed aptamer with the transfecting agent, Lipofectamine 2000 (Invitrogen), was dissolved in dimethyl sulfoxide (DMSO) for timeline studies (<xref rid="B33" ref-type="bibr">Zhou et al., 2008</xref>). Cell migration of both sample and control were monitored and compared to study the aptamer effect on cell migration.</p></sec></sec><sec id="S3"><title>Results and Discussion</title><sec id="S3.SS1"><title>S100A8 Network With Polycystic Ovary Syndrome Biomarkers</title><p>S100A8 interacts with 74 proteins (<xref ref-type="supplementary-material" rid="SM1">Supplementary File S1</xref>). The high confidential STRING network of S100A8 interactors has 55 nodes with 181 edges. The second network with biomarkers has 98 nodes with 431 edges; among 98, two proteins (SLC35D2, MORC4) are unconnected with the main network. Interactor network and biomarker network details are given in <xref ref-type="supplementary-material" rid="SM2">Supplementary Material</xref>. Merged network with connected nodes of the interactors and the biomarkers shows 96 nodes with 430 edges (interactions) that are illustrated in <xref ref-type="fig" rid="F1">Figure 1</xref>. Immediate interacting proteins with s100A8 are shown in yellow. By the network analysis, we found that S100A8 directly interact with 10 proteins (<xref rid="T1" ref-type="table">Table 1</xref>).</p><fig id="F1" position="float"><label>FIGURE 1</label><caption><p>Proposed mechanism of aptamer inhibition. Aptamer binds to the S100A8 and prevents the intracellular initial complexation with S100A9. Due to aptamer binding, extracellular receptor of advanced glycation end products (RAGE) complexed inflammatory sequences are also prevented.</p></caption><graphic xlink:href="fbioe-08-00328-g001"/></fig><fig id="F2" position="float"><label>FIGURE 2</label><caption><p>Merged network of Polycystic Ovary Syndrome (PCOS). Combined network of S100A8 integrators with PCOS biomarkers; yellow colored nodes are the first shell interacting proteins with S100A8 that are suspected for cyst migration activity.</p></caption><graphic xlink:href="fbioe-08-00328-g002"/></fig><table-wrap id="T1" position="float"><label>TABLE 1</label><caption><p>Proteins associated with S100A8 in the network.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Protein ID</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Name</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Polycystic Ovary Syndrome (PCOS) relative function</bold></td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">MMP9</td><td valign="top" align="left" rowspan="1" colspan="1">Matrix Metallopeptidase 9</td><td valign="top" align="left" rowspan="1" colspan="1">Proteolytic activity on the extracellular matrix (ECM) and involved in leukocyte migration</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RETN</td><td valign="top" align="left" rowspan="1" colspan="1">Resistin</td><td valign="top" align="left" rowspan="1" colspan="1">Promotes chemotaxis in myeloid cells</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CTSS</td><td valign="top" align="left" rowspan="1" colspan="1">Cathepsin S</td><td valign="top" align="left" rowspan="1" colspan="1">Endo protease involved in the removal of unwanted proteins</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">S100A9</td><td valign="top" align="left" rowspan="1" colspan="1">S100 Calcium Binding Protein A9</td><td valign="top" align="left" rowspan="1" colspan="1">Potent amplifier of inflammation as well as in cancer development and tumor spread</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NCF2</td><td valign="top" align="left" rowspan="1" colspan="1">Neutrophil Cytosolic Factor 2</td><td valign="top" align="left" rowspan="1" colspan="1">Involved in superoxide generation</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MPO</td><td valign="top" align="left" rowspan="1" colspan="1">Myeloperoxidase</td><td valign="top" align="left" rowspan="1" colspan="1">Produce hypochlorous acid and other toxic intermediates which enhance PMN microbicidal activity</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ALB</td><td valign="top" align="left" rowspan="1" colspan="1">Albumin</td><td valign="top" align="left" rowspan="1" colspan="1">Regulates blood plasma colloid osmotic pressure and acts as a carrier protein for hormones, fatty acids, metabolites, and exogenous drugs</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BECN1</td><td valign="top" align="left" rowspan="1" colspan="1">Beclin 1</td><td valign="top" align="left" rowspan="1" colspan="1">Mediates vesicle-trafficking processes, tumorigenesis, neurodegeneration, and apoptosis</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TP53</td><td valign="top" align="left" rowspan="1" colspan="1">Tumor Protein P53</td><td valign="top" align="left" rowspan="1" colspan="1">Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GRB2</td><td valign="top" align="left" rowspan="1" colspan="1">Growth Factor Receptor Bound Protein 2</td><td valign="top" align="left" rowspan="1" colspan="1">Adapter protein involved in the Ras signaling pathway</td></tr></tbody></table></table-wrap><p>A total of 246 ontology processes were found within the given significant <italic>p</italic>-value, among them, S100A8 is found in 88 different processes. Particularly, 10 ovulation and maturation-related GO terms with 14 proteins are identified in the enrichment analysis and are listed in <xref rid="T2" ref-type="table">Table 2</xref>. Apart from S100A8, RETN and S100A9 are found in both networks and also in enriched biological terms with high distribution. ESR1, GDF9, PDGFRA, and LEP are the other proteins found in a greater number of pathways comparatively in the selected terms. Distribution of proteins is given in the graph of <xref ref-type="fig" rid="F3">Figure 3A</xref>.</p><table-wrap id="T2" position="float"><label>TABLE 2</label><caption><p>Enriched terms of S100A8 in Polycystic Ovary Syndrome (PCOS).</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>GO term</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Group <italic>p</italic>-value</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>No. of proteins</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Associated proteins found</bold></td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Ovulation cycle</td><td valign="top" align="center" rowspan="1" colspan="1">2.11E-13</td><td valign="top" align="center" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">EGFR, ESR1, GDF9, HAS2, LEP, PDGFRA, RETN, S100A8, S100A9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Female sex differentiation</td><td valign="top" align="center" rowspan="1" colspan="1">6.47E-21</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1">CTNNA1, ESR1, GDF9, ICAM1, LEP, MYC, PDGFRA, RBP4, RETN, S100A8, S100A9, VEGFA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ovarian follicle development</td><td valign="top" align="center" rowspan="1" colspan="1">6.47E-21</td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">CTNNA1, ESR1, ICAM1, MYC, S100A8, S100A9, VEGFA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ovulation cycle</td><td valign="top" align="center" rowspan="1" colspan="1">1.38E-24</td><td valign="top" align="center" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">EGFR, ESR1, GDF9, HAS2, LEP, PDGFRA, RETN, S100A8, S100A9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ovulation cycle process</td><td valign="top" align="center" rowspan="1" colspan="1">1.38E-24</td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">ESR1, GDF9, LEP, PDGFRA, RETN, S100A8, S100A9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Development of primary female sexual characteristics</td><td valign="top" align="center" rowspan="1" colspan="1">1.38E-24</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">CTNNA1, ESR1, GDF9, ICAM1, LEP, MYC, PDGFRA, RETN, S100A8, S100A9, VEGFA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gonad development</td><td valign="top" align="center" rowspan="1" colspan="1">1.38E-24</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">CTNNA1, ESR1, GDF9, ICAM1, LEP, MYC, PDGFRA, RETN, S100A8, S100A9, VEGFA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ovarian follicle development</td><td valign="top" align="center" rowspan="1" colspan="1">1.38E-24</td><td valign="top" align="center" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">CTNNA1, ESR1, ICAM1, MYC, S100A8, S100A9, VEGFA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Female gonad development</td><td valign="top" align="center" rowspan="1" colspan="1">1.38E-24</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">CTNNA1, ESR1, GDF9, ICAM1, LEP, MYC, PDGFRA, RETN, S100A8, S100A9, VEGFA</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Regulation of female gonad development</td><td valign="top" align="center" rowspan="1" colspan="1">1.38E-24</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">GDF9, RETN, S100A8, S100A9</td></tr></tbody></table></table-wrap><fig id="F3" position="float"><label>FIGURE 3</label><caption><p>Gene ontology enrichment and structural properties of S100A8. <bold>(A)</bold> Distribution of proteins in polycystic ovary syndrome (PCOS)-related terms in enrichments. <bold>(B)</bold> Homo dimer crystal structure of S100A8&#x02014;global symmetric view. <bold>(C)</bold> High druggable pockets of S100A8&#x02014;shown in filled purple, sky blue, yellow, and orange colors. <bold>(D)</bold> Active sites of S100A8.</p></caption><graphic xlink:href="fbioe-08-00328-g003"/></fig></sec><sec id="S3.SS2"><title>Target Compatibility Evaluation</title><p>S100A8 is involved in seven GO functions which are positively regulated cyst formation and cancer cell migration. Additionally, S100A8 poses 18 pockets, among them, nine are druggable (score &#x0003e; 0.3) and four shows better cutoff scores (<xref rid="T3" ref-type="table">Table 3</xref>). Targets with low specificity on small-molecule were identified as poorly druggable targets (<xref rid="B2" ref-type="bibr">Barelier et al., 2010</xref>). Here we have found four high scored druggable pockets in the selected S100A8 (<xref ref-type="fig" rid="F3">Figure 3C</xref>). Structural features and active sites of S100A8 are shown in <xref ref-type="fig" rid="F3">Figures 3B,D</xref>, respectively. Due to the positive druggable results, it is considered as a notable target to control PCOS. Considerably, calcium-binding protein (S100A8) acts as a ligand for receptor of advanced glycation end products (RAGE) which is involved in many inflammatory and oncogenic pathways. There is evidence that S100A8 has a growth-promoting effect, and it helps cells to acquire cell migration activity through the RAGE binding pathway (<xref rid="B11" ref-type="bibr">Ghavami et al., 2008</xref>). S100A8 causes uteroplacental perfusion deficiency which leads to embryo abortion that supports the competence of our target selection (<xref rid="B25" ref-type="bibr">Sir-Petermann et al., 2002</xref>). Structural analysis shows that S100A8 has two helix loop helix Ca2+ binding domains known as EF-hands and exists as a complex with S100A9. Calprotectin is present in 1q21 locus of chromosome 1 in humans and has a molecular weight of 10&#x02013;12 kDa. During tumor development, chromosomal rearrangements take place in the locus of the S100A8 gene and majorly contribute to the cyst formation in PCOS. Also, serum calgranulin (S100A8 and S100A9) levels are higher in women with PCOS than normal women (<xref rid="B9" ref-type="bibr">Dai and Lu, 2012</xref>). This evidently shows that binding of S100A8 with RAGE facilitates the p38 mitogen-activated protein (MAP) kinase signaling through calcium phosphorylation which also governs cyst migration.</p><table-wrap id="T3" position="float"><label>TABLE 3</label><caption><p>Druggability assessment of S100A8 protein.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Pocket ID</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Volume A<sup>2</sup></bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Surface A<sup>2</sup></bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Drug score</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Simple score</bold></td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">P_0</td><td valign="top" align="center" rowspan="1" colspan="1">2,694.56</td><td valign="top" align="center" rowspan="1" colspan="1">2,620.71</td><td valign="top" align="center" rowspan="1" colspan="1">0.81</td><td valign="top" align="center" rowspan="1" colspan="1">0.61</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_1</td><td valign="top" align="center" rowspan="1" colspan="1">2,652.05</td><td valign="top" align="center" rowspan="1" colspan="1">2,822.45</td><td valign="top" align="center" rowspan="1" colspan="1">0.81</td><td valign="top" align="center" rowspan="1" colspan="1">0.64</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_3</td><td valign="top" align="center" rowspan="1" colspan="1">209.65</td><td valign="top" align="center" rowspan="1" colspan="1">195.14</td><td valign="top" align="center" rowspan="1" colspan="1">0.66</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_4</td><td valign="top" align="center" rowspan="1" colspan="1">180.41</td><td valign="top" align="center" rowspan="1" colspan="1">168.05</td><td valign="top" align="center" rowspan="1" colspan="1">0.6</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_2</td><td valign="top" align="center" rowspan="1" colspan="1">252.39</td><td valign="top" align="center" rowspan="1" colspan="1">481.15</td><td valign="top" align="center" rowspan="1" colspan="1">0.5</td><td valign="top" align="center" rowspan="1" colspan="1">0.14</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_6</td><td valign="top" align="center" rowspan="1" colspan="1">166.91</td><td valign="top" align="center" rowspan="1" colspan="1">273.52</td><td valign="top" align="center" rowspan="1" colspan="1">0.37</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_7</td><td valign="top" align="center" rowspan="1" colspan="1">165.23</td><td valign="top" align="center" rowspan="1" colspan="1">357.95</td><td valign="top" align="center" rowspan="1" colspan="1">0.37</td><td valign="top" align="center" rowspan="1" colspan="1">0.04</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_5</td><td valign="top" align="center" rowspan="1" colspan="1">173.21</td><td valign="top" align="center" rowspan="1" colspan="1">283.31</td><td valign="top" align="center" rowspan="1" colspan="1">0.35</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_8</td><td valign="top" align="center" rowspan="1" colspan="1">137.56</td><td valign="top" align="center" rowspan="1" colspan="1">211.73</td><td valign="top" align="center" rowspan="1" colspan="1">0.33</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_9</td><td valign="top" align="center" rowspan="1" colspan="1">130.58</td><td valign="top" align="center" rowspan="1" colspan="1">204.55</td><td valign="top" align="center" rowspan="1" colspan="1">0.28</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_10</td><td valign="top" align="center" rowspan="1" colspan="1">127.43</td><td valign="top" align="center" rowspan="1" colspan="1">196.55</td><td valign="top" align="center" rowspan="1" colspan="1">0.27</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_11</td><td valign="top" align="center" rowspan="1" colspan="1">120.91</td><td valign="top" align="center" rowspan="1" colspan="1">239.32</td><td valign="top" align="center" rowspan="1" colspan="1">0.27</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_14</td><td valign="top" align="center" rowspan="1" colspan="1">109.89</td><td valign="top" align="center" rowspan="1" colspan="1">180.88</td><td valign="top" align="center" rowspan="1" colspan="1">0.26</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_12</td><td valign="top" align="center" rowspan="1" colspan="1">117.99</td><td valign="top" align="center" rowspan="1" colspan="1">208.39</td><td valign="top" align="center" rowspan="1" colspan="1">0.25</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_13</td><td valign="top" align="center" rowspan="1" colspan="1">116.19</td><td valign="top" align="center" rowspan="1" colspan="1">209.36</td><td valign="top" align="center" rowspan="1" colspan="1">0.22</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_15</td><td valign="top" align="center" rowspan="1" colspan="1">109.89</td><td valign="top" align="center" rowspan="1" colspan="1">259.05</td><td valign="top" align="center" rowspan="1" colspan="1">0.16</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_16</td><td valign="top" align="center" rowspan="1" colspan="1">106.85</td><td valign="top" align="center" rowspan="1" colspan="1">216.05</td><td valign="top" align="center" rowspan="1" colspan="1">0.15</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P_17</td><td valign="top" align="center" rowspan="1" colspan="1">100.78</td><td valign="top" align="center" rowspan="1" colspan="1">249.25</td><td valign="top" align="center" rowspan="1" colspan="1">0.14</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap></sec><sec id="S3.SS3"><title>Construction of RNA Analog Library Using Glucocorticoid Response Element</title><p>The fragment-based approach of aptamer docking yielded better interaction with S100A8. By the RNA-Lim method, 18 fragments with the consensus sequence of GRE were constructed and used for binding analysis (<xref ref-type="fig" rid="F4">Figure 4A</xref>). Frag6, Frag9, and Frag10 showed better interaction (<xref rid="T4" ref-type="table">Table 4</xref>) in the active domain of target with minimal global binding energy. Among the three possible conformations, sequence 1 (<xref ref-type="fig" rid="F4">Figure 4B</xref>) shows better thermal stability and lowest energy than the other two sequences. Optimal structure with a folding simulation at physiological pH shows there are three nucleotides at positions 4&#x02013;7 that make intramolecular base pairing for loop structure (<xref ref-type="fig" rid="F4">Figure 4C</xref>). Energy minimized aptamers are significantly stable, and the aptamers with a binding energy of &#x02265;-40 are optimal in the therapeutical aspect (<xref rid="B20" ref-type="bibr">Pagano et al., 2008</xref>). Oligo fragments selected are by their binding ability on the active sites of the target. The compiled 18-mer binds effectively than the fragments. Stability comparison among the newly constructed aptamer sequences is stated in <xref rid="T5" ref-type="table">Table 5</xref>. Among the three, Apt1 has high stability with a melting temperature of 41.8&#x000b0;C, and also the simulation studies confirmed that it requires the minimum free energy (&#x02013;27.93 kcal/mol) for hairpin loop formation. In addition, the Apt1 fragment poses low molecular weight (5,327.4 g/mol) comparatively. Aptamers in practice are available in the range of 15&#x02013;81 nucleotide length with higher molecular weights (<xref rid="B24" ref-type="bibr">Shigdar et al., 2013</xref>), but here, the designed is 18-mer with lower molecular weight so the plasma clearance may be faster.</p><fig id="F4" position="float"><label>FIGURE 4</label><caption><p>RNA library and structures. <bold>(A)</bold> Library construction by RNA-Lim method using the consensus sequence of glucocorticoid response element (GRE). <bold>(B)</bold> 3D structure of potential aptamer candidate. <bold>(C)</bold> Sequence and physiological structure of aptamer after optimal simulation and folding, and the color of bases indicates their energy levels.</p></caption><graphic xlink:href="fbioe-08-00328-g004"/></fig><table-wrap id="T4" position="float"><label>TABLE 4</label><caption><p>Binding energies of RNA analog fragments with S100A8.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Fragments</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Predicted &#x00394;G (kcal/mol)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Fragments</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Predicted &#x00394;G (kcal/mol)</bold></td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Frag 1</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;16.24</td><td valign="top" align="center" rowspan="1" colspan="1">Frag 10</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;30.51</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frag 2</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;8.55</td><td valign="top" align="center" rowspan="1" colspan="1">Frag 11</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;14.34</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frag 3</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;16.52</td><td valign="top" align="center" rowspan="1" colspan="1">Frag 12</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;15.66</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frag 4</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;51.85</td><td valign="top" align="center" rowspan="1" colspan="1">Frag 13</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;15.17</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frag 5</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;18.46</td><td valign="top" align="center" rowspan="1" colspan="1">Frag 14</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;11.21</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frag 6</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;31.71</td><td valign="top" align="center" rowspan="1" colspan="1">Frag 15</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;18.70</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frag 7</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;16.54</td><td valign="top" align="center" rowspan="1" colspan="1">Frag 16</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;10.68</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frag 8</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;13.17</td><td valign="top" align="center" rowspan="1" colspan="1">Frag 17</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;21.76</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frag 9</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;38.76</td><td valign="top" align="center" rowspan="1" colspan="1">Frag 18</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;23.71</td></tr></tbody></table></table-wrap><table-wrap id="T5" position="float"><label>TABLE 5</label><caption><p>Aptamer stability comparison.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold>Aptamers</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>GC content (%)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Tm (&#x000b0;C)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Molecular weight (g/mol)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>&#x00394;Gmax (kcal/mol)</bold></td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Apt1</td><td valign="top" align="center" rowspan="1" colspan="1">CAUCAUCAUGUUAUGUUC</td><td valign="top" align="center" rowspan="1" colspan="1">33.3</td><td valign="top" align="center" rowspan="1" colspan="1">41.8</td><td valign="top" align="center" rowspan="1" colspan="1">5327.4</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;27.93</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Apt2</td><td valign="top" align="center" rowspan="1" colspan="1">AACAUCACAGAAGACAGA</td><td valign="top" align="center" rowspan="1" colspan="1">38.9</td><td valign="top" align="center" rowspan="1" colspan="1">37</td><td valign="top" align="center" rowspan="1" colspan="1">5504.7</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;28.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Apt3</td><td valign="top" align="center" rowspan="1" colspan="1">CUGACAACAUCAAUCAUG</td><td valign="top" align="center" rowspan="1" colspan="1">38.9</td><td valign="top" align="center" rowspan="1" colspan="1">36.6</td><td valign="top" align="center" rowspan="1" colspan="1">5395.5</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;29.04</td></tr></tbody></table></table-wrap></sec><sec id="S3.SS4"><title>Interaction, Inhibition, and Stability Studies</title><p>Primarily, RAGE being the receptor for S100A8 was docked to confirm for its binding ability in the domain, which may affect the binding of the designed aptamer. As a result of protein&#x02013;protein docking analysis, Arg 114 residue at A domain of RAGE interacting with Gln 44 residue at H domain of S100A8 is found as the most active interaction. To test the comparison of binding interactions, RAGE was docked with GRE, which resulted in a binding energy of &#x02013;24.38, comparatively higher than its binding with the designed aptamers (&#x02013;46.33) that is shown in <xref rid="T6" ref-type="table">Table 6</xref>; this infers that the designed nucleotide aptamer also binds efficiently at the S100A8 binding domain of RAGE (<xref ref-type="fig" rid="F5">Figures 5B,C</xref>). In parallel, interactions of S100A8 with GRE and S100A8 with the designed aptamer were inspected to find the competency, which was found as &#x02013;22.11 and &#x02013;45.32 energy levels, respectively. The designed aptamer binds efficiently in the active dimer of the target (<xref ref-type="fig" rid="F5">Figure 5A</xref>).</p><table-wrap id="T6" position="float"><label>TABLE 6</label><caption><p>Docking results.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Protein</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Target</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>Binding site</bold></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>Global energy</bold></td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">RAGE</td><td valign="top" align="center" rowspan="1" colspan="1">S100A8</td><td valign="top" align="left" rowspan="1" colspan="1">Arg A 114 &#x02192; Gln H44</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;25.75</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RAGE</td><td valign="top" align="center" rowspan="1" colspan="1">GRE</td><td valign="top" align="left" rowspan="1" colspan="1">Arg B 203 &#x02192; U<sub>14,</sub> Arg B 228 &#x02192; G<sub>17</sub></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;24.38</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">S100A8</td><td valign="top" align="center" rowspan="1" colspan="1">GRE</td><td valign="top" align="left" rowspan="1" colspan="1">Asn D 61 &#x02192; C<sub>6,</sub> Ala B 1 &#x02192; U<sub>13</sub></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;22.11</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RAGE</td><td valign="top" align="center" rowspan="1" colspan="1">Aptamer</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Try B 118 &#x02192; A<sub>13,</sub> Arg B 216 &#x02192; A<sub>13</sub></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;46.33</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Arg B 218 &#x02192; G<sub>10,</sub> Asn B 25 &#x02192; U<sub>16</sub></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Gln B 24 &#x02192; U<sub>16</sub></td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">S100A8</td><td valign="top" align="center" rowspan="1" colspan="1">Aptamer</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Lys B 36 &#x02192; U<sub>9,</sub> Lys F 48 &#x02192; U<sub>17</sub></td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;45.32</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Ser H 86 &#x02192; A<sub>13,</sub> Asp C 32 &#x02192; G<sub>10</sub></td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02022; Lys B 18 &#x02192; G<sub>10,</sub> Lys B 21 &#x02192; G<sub>10</sub></td><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><fig id="F5" position="float"><label>FIGURE 5</label><caption><p>Mechanism of inhibition and docking with RNA aptamer. <bold>(A)</bold> Aptamer bases binding at the active sites of S100A8. <bold>(B)</bold> Binding pose of aptamer on receptor of advanced glycation end products (RAGE) protein. <bold>(C)</bold> Optimal binding pose of aptamer on the S100A8.</p></caption><graphic xlink:href="fbioe-08-00328-g005"/></fig></sec><sec id="S3.SS5"><title>Anti-cell Migration Assay on MCF-7 Cell Line</title><p>Within 4 h of scratch, development of closure was seen in the control (which does not have aptamer), the wounded area has turned into a normal layer when compared with the initial image of well. In the aptamer well, there is no cell migration observed even after the fourth hour of incubation, it was confirmed in the images of 0 and 4 h of wounded well (<xref ref-type="fig" rid="F6">Figure 6</xref>).</p><fig id="F6" position="float"><label>FIGURE 6</label><caption><p>Wound scratch assay. Cell migration studies by wound healing assay on MCF7 cell line. Leitz labovert FS inverted microscope was used to view the cell migration. <bold>(A)</bold> A 4 mm scratch with a sterile tip at 0 h, and the wound is pointed at with an arrowhead in the 10 &#x000d7; magnified illustration. <bold>(B)</bold> Ten times magnified view of aptamer incubated (4 h) cell line. No cell migration was observed after 4 h of aptamer incubation. <bold>(C)</bold> Fifty times magnification of scratch in control plate (cell migration seen) after the fourth hour.</p></caption><graphic xlink:href="fbioe-08-00328-g006"/></fig></sec></sec><sec id="S4"><title>Conclusion</title><p>From the network analysis, S100A8 is identified as a targetable protein to control PCOS. The druggable property of the target was validated by topological measures. S100A8 acts as a ligand for RAGE to promote cell migration in cancers and PCOS conditions. GRE inhibits S100A8 by competitive binding at the minimal level through a feedback mechanism. Additionally, S100A9 and resistin were also found along with S100A8 as associative proteins. We adopted a computational method to develop an RNA aptamer and designed 18 oligos based on the consensus sequences of GRE, which binds to both RAGE and S100A8. In addition to the computational studies, the cell line studies proved the anti-migration activity of the designed aptamer at minimal dose delivery with Lipofectamine 2000. The newly designed 18mer effectively stopped the cancer cell migration through dual action, and it is identified as a potential therapeutic to control PCOS and cancers.</p></sec><sec sec-type="data-availability" id="S5"><title>Data Availability Statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.</p></sec><sec id="S6"><title>Author Contributions</title><p>All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.</p></sec><sec id="conf1"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>We thank the scientific committee of Kamaraj College of Engineering and Technology for their encouragement with best project award in TECHNOVISION&#x02019;17. Our sincere thanks to Tamil Nadu State Council for Science and Technology (TNSCST), Directorate of Technical Education, Chennai, for their partial financial support through student project scheme. I dedicate this manuscript as a gift to my student A. Shobana for her recent birthday. This manuscript has been released as a pre-print at bioRxiv (<ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/603357v1">https://www.biorxiv.org/content/10.1101/603357v1</ext-link>), doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/https://doi.org/10.1101/603357">https://doi.org/10.1101/603357</ext-link> entitled &#x0201c;<italic>Identification of target candidate in polycystic ovarian syndrome and in vitro evaluation of therapeutic activity of the designed RNA aptamer</italic>,&#x0201d; and this is a revised version.</p></ack><sec id="S8" sec-type="supplementary material"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fbioe.2020.00328/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fbioe.2020.00328/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Table_1.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM2"><media xlink:href="Image_1.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahirwar</surname><given-names>R.</given-names></name><name><surname>Smita</surname><given-names>N.</given-names></name><name><surname>Shikha</surname><given-names>A.</given-names></name><name><surname>Srinivasan</surname><given-names>R.</given-names></name><name><surname>Souvik</surname><given-names>M.</given-names></name><name><surname>Pradip</surname><given-names>N.</given-names></name></person-group> (<year>2016</year>). <article-title>In silico selection of an aptamer to estrogen receptor alpha using computational docking employing estrogen response elements as aptamer-alike molecules.</article-title>
<source><italic>Sci. Rep.</italic></source>
<volume>6</volume>:<issue>21285</issue>. <pub-id pub-id-type="doi">10.1038/srep21285</pub-id>
<?supplied-pmid 26899418?><pub-id pub-id-type="pmid">26899418</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barelier</surname><given-names>S.</given-names></name><name><surname>Pons</surname><given-names>J.</given-names></name><name><surname>Gehring</surname><given-names>K.</given-names></name><name><surname>Lancelin</surname><given-names>J.-M.</given-names></name><name><surname>Krimm</surname><given-names>I.</given-names></name></person-group> (<year>2010</year>). <article-title>Ligand specificity in fragment-based drug design.</article-title>
<source><italic>J. Med. Chem.</italic></source>
<volume>53</volume>
<fpage>5256</fpage>&#x02013;<lpage>5266</lpage>. <pub-id pub-id-type="doi">10.1021/jm100496j</pub-id>
<?supplied-pmid 20575554?><pub-id pub-id-type="pmid">20575554</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berezovski</surname><given-names>M. V.</given-names></name><name><surname>Musheev</surname><given-names>M. U.</given-names></name><name><surname>Drabovich</surname><given-names>A. P.</given-names></name><name><surname>Jitkova</surname><given-names>J. V.</given-names></name><name><surname>Krylov</surname><given-names>S. N.</given-names></name></person-group> (<year>2006</year>). <article-title>Non-SELEX: selection of aptamers without intermediate amplification of candidate oligonucleotides.</article-title>
<source><italic>Nat. Protoc.</italic></source>
<volume>1</volume>:<issue>1359</issue>. <pub-id pub-id-type="doi">10.1038/nprot.2006.200</pub-id>
<?supplied-pmid 17406423?><pub-id pub-id-type="pmid">17406423</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biesiada</surname><given-names>M.</given-names></name><name><surname>Pachulska-Wieczorek</surname><given-names>K.</given-names></name><name><surname>Adamiak</surname><given-names>R. W.</given-names></name><name><surname>Purzycka</surname><given-names>K. J.</given-names></name></person-group> (<year>2016</year>). <article-title>RNAComposer and RNA 3D structure prediction for nanotechnology.</article-title>
<source><italic>Methods</italic></source>
<volume>103</volume>
<fpage>120</fpage>&#x02013;<lpage>127</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymeth.2016.03.010</pub-id>
<?supplied-pmid 27016145?><pub-id pub-id-type="pmid">27016145</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bindea</surname><given-names>G.</given-names></name><name><surname>Bernhard</surname><given-names>M.</given-names></name><name><surname>Hubert</surname><given-names>H.</given-names></name><name><surname>Pornpimol</surname><given-names>C.</given-names></name><name><surname>Marie</surname><given-names>T.</given-names></name><name><surname>Amos</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks.</article-title>
<source><italic>Bioinformatics</italic></source>
<volume>25</volume>
<fpage>1091</fpage>&#x02013;<lpage>1093</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btp101</pub-id>
<?supplied-pmid 19237447?><pub-id pub-id-type="pmid">19237447</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camorani</surname><given-names>S.</given-names></name><name><surname>Esposito</surname><given-names>C. L.</given-names></name><name><surname>Rienzo</surname><given-names>A.</given-names></name><name><surname>Catuogno</surname><given-names>S.</given-names></name><name><surname>Iaboni</surname><given-names>M.</given-names></name><name><surname>Condorelli</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRbeta aptamer.</article-title>
<source><italic>Mol. Ther.</italic></source>
<volume>22</volume>
<fpage>828</fpage>&#x02013;<lpage>841</lpage>. <pub-id pub-id-type="doi">10.1038/mt.2013.300</pub-id>
<?supplied-pmid 24566984?><pub-id pub-id-type="pmid">24566984</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croft</surname><given-names>D.</given-names></name><name><surname>O&#x02019;Kelly</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Haw</surname><given-names>R.</given-names></name><name><surname>Gillespie</surname><given-names>M.</given-names></name><name><surname>Matthews</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Reactome: a database of reactions, pathways and biological processes.</article-title>
<source><italic>Nucleic Acids Res.</italic></source>
<volume>39</volume>
<fpage>D691</fpage>&#x02013;<lpage>D697</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkq1018</pub-id>
<?supplied-pmid 21067998?><pub-id pub-id-type="pmid">21067998</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daan</surname><given-names>N. M.</given-names></name><name><surname>Koster</surname><given-names>M. P.</given-names></name><name><surname>de Wilde</surname><given-names>M. A.</given-names></name><name><surname>Dalmeijer</surname><given-names>G. W.</given-names></name><name><surname>Evelein</surname><given-names>A. M.</given-names></name><name><surname>Fauser</surname><given-names>B. C.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Biomarker profiles in women with PCOS and PCOS Offspring; a pilot study.</article-title>
<source><italic>PLoS One</italic></source>
<volume>11</volume>:<issue>e0165033</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0165033</pub-id>
<?supplied-pmid 27806063?><pub-id pub-id-type="pmid">27806063</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>G.</given-names></name><name><surname>Lu</surname><given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>Different protein expression patterns associated with polycystic ovary syndrome in human follicular fluid during controlled ovarian hyperstimulation.</article-title>
<source><italic>Reprod Fertil. Dev.</italic></source>
<volume>24</volume>
<fpage>893</fpage>&#x02013;<lpage>904</lpage>. <pub-id pub-id-type="doi">10.1071/RD11201</pub-id>
<?supplied-pmid 22935150?><pub-id pub-id-type="pmid">22935150</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerashchenko</surname><given-names>T. S.</given-names></name><name><surname>Nikita</surname><given-names>M. N.</given-names></name><name><surname>Nadezhda</surname><given-names>V. K.</given-names></name><name><surname>Sofia</surname><given-names>Y. Z.</given-names></name><name><surname>Marina</surname><given-names>V. Z.</given-names></name><name><surname>Nadezhda</surname><given-names>V.</given-names></name></person-group> (<year>2019</year>). <article-title>Markers of cancer cell invasion: are they good enough?</article-title>
<source><italic>J. Clin. Med.</italic></source>
<volume>8</volume>:<issue>1092</issue>. <pub-id pub-id-type="doi">10.3390/jcm8081092</pub-id>
<?supplied-pmid 31344926?><pub-id pub-id-type="pmid">31344926</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghavami</surname><given-names>S.</given-names></name><name><surname>Rashedi</surname><given-names>I.</given-names></name><name><surname>Dattilo</surname><given-names>B. M.</given-names></name><name><surname>Eshraghi</surname><given-names>M.</given-names></name><name><surname>Chazin</surname><given-names>W. J.</given-names></name><name><surname>Hashemi</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway.</article-title>
<source><italic>J. Leukoc. Biol.</italic></source>
<volume>83</volume>
<fpage>1484</fpage>&#x02013;<lpage>1492</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.0607397</pub-id>
<?supplied-pmid 18339893?><pub-id pub-id-type="pmid">18339893</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghavami</surname><given-names>S.</given-names></name><name><surname>Seth</surname><given-names>C.</given-names></name><name><surname>Mohammad</surname><given-names>H.</given-names></name><name><surname>Mehdi</surname><given-names>E.</given-names></name><name><surname>Walter</surname><given-names>J. C.</given-names></name><name><surname>Andrew</surname><given-names>J. H.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>S100A8/A9: a janus-faced molecule in cancer therapy and tumorgenesis.</article-title>
<source><italic>Eur. J. Pharmacol.</italic></source>
<volume>625</volume>
<fpage>73</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2009.08.044</pub-id>
<?supplied-pmid 19835859?><pub-id pub-id-type="pmid">19835859</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Yamashita</surname><given-names>K.</given-names></name><name><surname>Azuma</surname><given-names>R.</given-names></name><name><surname>Carver</surname><given-names>J. A.</given-names></name><name><surname>Standley</surname><given-names>D. M.</given-names></name></person-group> (<year>2015</year>). <article-title>RNA-LIM: a novel procedure for analyzing protein/single-stranded RNA propensity data with concomitant estimation of interface structure.</article-title>
<source><italic>Anal. Biochem.</italic></source>
<volume>472</volume>
<fpage>52</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.ab.2014.11.004</pub-id>
<?supplied-pmid 25479604?><pub-id pub-id-type="pmid">25479604</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>K.</given-names></name><name><surname>Passey</surname><given-names>R. J.</given-names></name><name><surname>Endoh</surname><given-names>Y.</given-names></name><name><surname>Rahimi</surname><given-names>F.</given-names></name><name><surname>Youssef</surname><given-names>P. P.</given-names></name><name><surname>Yen</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Regulation of S100A8 by glucocorticoids.</article-title>
<source><italic>J. Immunol.</italic></source>
<volume>174</volume>
<fpage>2318</fpage>&#x02013;<lpage>2326</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.174.4.2318</pub-id>
<?supplied-pmid 15699168?><pub-id pub-id-type="pmid">15699168</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Xiaoqin</surname><given-names>L.</given-names></name><name><surname>Lin</surname><given-names>W.</given-names></name><name><surname>Ning</surname><given-names>J.</given-names></name><name><surname>Jun</surname><given-names>Y.</given-names></name><name><surname>Xiaobo</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Integrated analyses for genetic markers of polycystic ovary syndrome with 9 case-control studies of gene expression profiles.</article-title>
<source><italic>Oncotarget</italic></source>
<volume>8</volume>
<fpage>3170</fpage>&#x02013;<lpage>3180</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.13881</pub-id>
<?supplied-pmid 27965459?><pub-id pub-id-type="pmid">27965459</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mashiach</surname><given-names>E.</given-names></name><name><surname>Schneidman-Duhovny</surname><given-names>D.</given-names></name><name><surname>Andrusier</surname><given-names>N.</given-names></name><name><surname>Nussinov</surname><given-names>R.</given-names></name><name><surname>Wolfson</surname><given-names>H. J.</given-names></name></person-group> (<year>2008</year>). <article-title>FireDock: a web server for fast interaction refinement in molecular docking.</article-title>
<source><italic>Nucleic Acids Res.</italic></source>
<volume>36</volume>
<fpage>W229</fpage>&#x02013;<lpage>W232</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkn186</pub-id>
<?supplied-pmid 18424796?><pub-id pub-id-type="pmid">18424796</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nioi</surname><given-names>P.</given-names></name><name><surname>McMahon</surname><given-names>M.</given-names></name><name><surname>Itoh</surname><given-names>K.</given-names></name><name><surname>Yamamoto</surname><given-names>M.</given-names></name><name><surname>Hayes</surname><given-names>J. D.</given-names></name></person-group> (<year>2003</year>). <article-title>Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence.</article-title>
<source><italic>Biochem. J.</italic></source>
<volume>374</volume>(<issue>Pt 2</issue>), <fpage>337</fpage>&#x02013;<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1042/bj20030754</pub-id>
<?supplied-pmid 12816537?><pub-id pub-id-type="pmid">12816537</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oughtred</surname><given-names>R.</given-names></name><name><surname>Chris</surname><given-names>S.</given-names></name><name><surname>Bobby-Joe</surname><given-names>B.</given-names></name><name><surname>Jennifer</surname><given-names>R.</given-names></name><name><surname>Lorrie</surname><given-names>B.</given-names></name><name><surname>Christie</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>The BioGRID interaction database: 2019 update.</article-title>
<source><italic>Nucleic Acids Res.</italic></source>
<volume>47</volume>
<fpage>D529</fpage>&#x02013;<lpage>D541</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1079</pub-id>
<?supplied-pmid 30476227?><pub-id pub-id-type="pmid">30476227</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owczarzy</surname><given-names>R.</given-names></name><name><surname>Tataurov</surname><given-names>A. V.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Manthey</surname><given-names>J. A.</given-names></name><name><surname>McQuisten</surname><given-names>K. A.</given-names></name><name><surname>Almabrazi</surname><given-names>H. G.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>IDT SciTools: a suite for analysis and design of nucleic acid oligomers.</article-title>
<source><italic>Nucleic Acids Res.</italic></source>
<volume>36</volume>
<fpage>W163</fpage>&#x02013;<lpage>W169</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkn198</pub-id>
<?supplied-pmid 18440976?><pub-id pub-id-type="pmid">18440976</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagano</surname><given-names>B.</given-names></name><name><surname>Martino</surname><given-names>L.</given-names></name><name><surname>Randazzo</surname><given-names>A.</given-names></name><name><surname>Giancola</surname><given-names>C.</given-names></name></person-group> (<year>2008</year>). <article-title>Stability and binding properties of a modified thrombin binding aptamer.</article-title>
<source><italic>Biophys. J.</italic></source>
<volume>94</volume>
<fpage>562</fpage>&#x02013;<lpage>569</lpage>. <pub-id pub-id-type="doi">10.1529/biophysj.107.117382</pub-id>
<?supplied-pmid 17890401?><pub-id pub-id-type="pmid">17890401</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parisien</surname><given-names>M.</given-names></name><name><surname>Major</surname><given-names>F.</given-names></name></person-group> (<year>2008</year>). <article-title>The MC-Fold and MC-Sym pipeline infers RNA structure from sequence data.</article-title>
<source><italic>Nature</italic></source>
<volume>452</volume>
<fpage>51</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1038/nature06684</pub-id>
<?supplied-pmid 18322526?><pub-id pub-id-type="pmid">18322526</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rees</surname><given-names>B. B.</given-names></name><name><surname>Bowman</surname><given-names>J. A.</given-names></name><name><surname>Schulte</surname><given-names>P. M.</given-names></name></person-group> (<year>2001</year>). <article-title>Structure and sequence conservation of a putative hypoxia response element in the lactate dehydrogenase-B gene of Fundulus.</article-title>
<source><italic>Biol. Bull.</italic></source>
<volume>200</volume>
<fpage>247</fpage>&#x02013;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.2307/1543505</pub-id>
<?supplied-pmid 11441966?><pub-id pub-id-type="pmid">11441966</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneidman-Duhovny</surname><given-names>D.</given-names></name><name><surname>Inbar</surname><given-names>Y.</given-names></name><name><surname>Nussinov</surname><given-names>R.</given-names></name><name><surname>Wolfson</surname><given-names>H. J.</given-names></name></person-group> (<year>2005</year>). <article-title>PatchDock and SymmDock: servers for rigid and symmetric docking.</article-title>
<source><italic>Nucleic Acids Res.</italic></source>
<volume>33</volume>
<fpage>W363</fpage>&#x02013;<lpage>W367</lpage>. <?supplied-pmid 15980490?><pub-id pub-id-type="pmid">15980490</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shigdar</surname><given-names>S.</given-names></name><name><surname>Qiao</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>S.-F.</given-names></name><name><surname>Xiang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>RNA aptamers targeting cancer stem cell marker CD133.</article-title>
<source><italic>Cancer Lett.</italic></source>
<volume>330</volume>
<fpage>84</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2012.11.032</pub-id>
<?supplied-pmid 23196060?><pub-id pub-id-type="pmid">23196060</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sir-Petermann</surname><given-names>T.</given-names></name><name><surname>Maliqueo</surname><given-names>M.</given-names></name><name><surname>Angel</surname><given-names>B.</given-names></name><name><surname>Lara</surname><given-names>H. E.</given-names></name><name><surname>P&#x000e9;rez-Bravo</surname><given-names>F.</given-names></name><name><surname>Recabarren</surname><given-names>S. E.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization.</article-title>
<source><italic>Hum. Reprod.</italic></source>
<volume>17</volume>
<fpage>2573</fpage>&#x02013;<lpage>2579</lpage>. <pub-id pub-id-type="doi">10.1093/humrep/17.10.2573</pub-id>
<?supplied-pmid 12351531?><pub-id pub-id-type="pmid">12351531</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strimbu</surname><given-names>K.</given-names></name><name><surname>Tavel</surname><given-names>J. A.</given-names></name></person-group> (<year>2010</year>). <article-title>What are biomarkers?</article-title>
<source><italic>Curr. Opin. HIV AIDS</italic></source>
<volume>5</volume>
<fpage>463</fpage>&#x02013;<lpage>466</lpage>. <pub-id pub-id-type="doi">10.1097/COH.0b013e32833ed177</pub-id>
<?supplied-pmid 20978388?><pub-id pub-id-type="pmid">20978388</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D.</given-names></name><name><surname>Annika</surname><given-names>L. G.</given-names></name><name><surname>David</surname><given-names>L.</given-names></name><name><surname>Alexander</surname><given-names>J.</given-names></name><name><surname>Stefan</surname><given-names>W.</given-names></name><name><surname>Jaime</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets.</article-title>
<source><italic>Nucleic Acids Res.</italic></source>
<volume>47</volume>
<fpage>D607</fpage>&#x02013;<lpage>D613</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id>
<?supplied-pmid 30476243?><pub-id pub-id-type="pmid">30476243</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>B. K.</given-names></name><name><surname>Raghu</surname><given-names>A.</given-names></name><name><surname>Jing</surname><given-names>C.</given-names></name><name><surname>Hendrik</surname><given-names>L.</given-names></name><name><surname>Louis</surname><given-names>J. S. C.</given-names></name><name><surname>Harpal</surname><given-names>S. R.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells.</article-title>
<source><italic>J. Clin. Endocrinol. Metab.</italic></source>
<volume>96</volume>
<fpage>808</fpage>&#x02013;<lpage>816</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2010-1803</pub-id>
<?supplied-pmid 21190977?><pub-id pub-id-type="pmid">21190977</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>C. Y.</given-names></name><name><surname>Ashrafuzzaman</surname><given-names>M.</given-names></name><name><surname>Mane</surname><given-names>J. Y.</given-names></name><name><surname>Kapty</surname><given-names>J.</given-names></name><name><surname>Mercer</surname><given-names>J. R.</given-names></name><name><surname>Tuszynski</surname><given-names>J. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Entropic fragment-based approach to aptamer design.</article-title>
<source><italic>Chem. Biol. Drug Des.</italic></source>
<volume>78</volume>
<fpage>1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1111/j.1747-0285.2011.01125.x</pub-id>
<?supplied-pmid 21496214?><pub-id pub-id-type="pmid">21496214</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkamer</surname><given-names>A.</given-names></name><name><surname>Kuhn</surname><given-names>D.</given-names></name><name><surname>Rippmann</surname><given-names>F.</given-names></name><name><surname>Rarey</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>DoGSiteScorer: a web server for automatic binding site prediction, analysis and druggability assessment.</article-title>
<source><italic>Bioinformatics</italic></source>
<volume>28</volume>
<fpage>2074</fpage>&#x02013;<lpage>2075</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bts310</pub-id>
<?supplied-pmid 22628523?><pub-id pub-id-type="pmid">22628523</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weikum</surname><given-names>E. R.</given-names></name><name><surname>Knuesel</surname><given-names>M. T.</given-names></name><name><surname>Ortlund</surname><given-names>E. A.</given-names></name><name><surname>Yamamoto</surname><given-names>K. R.</given-names></name></person-group> (<year>2017</year>). <article-title>Glucocorticoid receptor control of transcription: precision and plasticity via allostery.</article-title>
<source><italic>Nat. Rev. Mol. Cell Biol.</italic></source>
<volume>18</volume>
<fpage>159</fpage>&#x02013;<lpage>174</lpage>. <pub-id pub-id-type="doi">10.1038/nrm.2016.152</pub-id>
<?supplied-pmid 28053348?><pub-id pub-id-type="pmid">28053348</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Sugawara</surname><given-names>M.</given-names></name><name><surname>Ponath</surname><given-names>P. D.</given-names></name><name><surname>Wessendorf</surname><given-names>L.</given-names></name><name><surname>Banerji</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>1990</year>). <article-title>Interferon gamma response region in the promoter of the human DPA gene.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>87</volume>
<fpage>9226</fpage>&#x02013;<lpage>9230</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.87.23.9226</pub-id>
<?supplied-pmid 2123552?><pub-id pub-id-type="pmid">2123552</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Zaia</surname><given-names>J.</given-names></name><name><surname>Rossi</surname><given-names>J. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.</article-title>
<source><italic>Mol. Ther.</italic></source>
<volume>16</volume>
<fpage>1481</fpage>&#x02013;<lpage>1489</lpage>. <pub-id pub-id-type="doi">10.1038/mt.2008.92</pub-id>
<?supplied-pmid 18461053?><pub-id pub-id-type="pmid">18461053</pub-id></mixed-citation></ref></ref-list></back></article>